ORG-25435

ORG-25435

ORG-25435 is a chemical compound that is classified as a NMDA receptor antagonist. It was developed by Organon International, a pharmaceutical company that is now part of MSD. ORG-25435 has been studied for its potential use in the treatment of various neurological disorders, including schizophrenia and Alzheimer's disease.

History

ORG-25435 was first synthesized by Organon International in the late 20th century. The compound was part of the company's efforts to develop new treatments for neurological disorders. The development of ORG-25435 was based on the hypothesis that NMDA receptor antagonists could have therapeutic effects in conditions such as schizophrenia and Alzheimer's disease.

Pharmacology

ORG-25435 is a non-competitive NMDA receptor antagonist. The NMDA receptor is a type of ionotropic glutamate receptor that plays a key role in neuronal plasticity and memory function. By blocking the activity of this receptor, ORG-25435 can potentially modulate the neurotransmission of glutamate, the most abundant excitatory neurotransmitter in the human brain.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of ORG-25435. These trials have focused on its potential use in the treatment of schizophrenia and Alzheimer's disease. However, the results have been mixed, and further research is needed to fully understand the therapeutic potential of this compound.

See Also

• NMDA receptor antagonist
• Organon International
• Schizophrenia
• Alzheimer's disease

References

<references />

This article is a stub related to chemistry. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!